Journal of Family Medicine and Primary Care (Jan 2022)

Estimation of anti-SARS-CoV-2 IgG titre among blood donors in Ranchi

  • Sushma Kumari,
  • Usha Saroj,
  • Ashwini Verma,
  • Abhay Kumar

DOI
https://doi.org/10.4103/jfmpc.jfmpc_727_22
Journal volume & issue
Vol. 11, no. 10
pp. 6385 – 6389

Abstract

Read online

Introduction: Coronavirus disease 2019 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as novel coronavirus (2019-nCoV). The disease presentation ranges from asymptomatic to severe acute respiratory failure requiring intensive care support. Anti-SARS-CoV-2 IgG antibodies are developed either by natural infection from SARS-CoV-2 or by vaccination against COVID-19. The persistence of IgG antibodies allows identification of the people who have been infected in the past, recovered from illness, and possibly become immune.7 IgG detection and other serological assays will play an important role in research and surveillance. Aims and Objective: The objective of the study is to assess anti-SARS-CoV-2 IgG titre among blood donors and to assess the decreasing incidence of COVID-19 in the department of blood bank, Rajendra Institute of Medical Sciences, Ranchi, Jharkhand. Materials and Methods: An observational, cross-sectional study was conducted at the department of blood bank, Rajendra Institute of Medical Sciences, Ranchi, Jharkhand over a period of 2 months and 14 days from 06 February 2021 to 20 April 2021 who donated at least one unit of blood. Results: This study recorded a greater number of male donors with B+ blood group. The anti-SARS-CoV-2 titre were mostly young adults between 18 and 31 years of age. Conclusion: Seroprevalence was high in males having blood group B+ between 18 and 32 years of age.

Keywords